ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, INCLISIRAN
CKJX839A12402
Approved small_molecule active
Quick answer
ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, INCLISIRAN for Hypercholesterolemia is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Hypercholesterolemia
- Phase
- Approved
- Modality
- small_molecule
- Status
- active